Bolus fibrinolytic therapy in acute myocardial infarction

Journal of the American Medical Association

Volumn 286, Issue 4, 2001, Pages 442-449

  Llevadot, Joan ^a   Giugliano, Robert P ^a   Antman, Elliott M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT; HEPARIN; LANOTEPLASE; RETEPLASE; TENECTEPLASE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ANGIOGRAPHY; ARTICLE; BOLUS INJECTION; BRAIN HEMORRHAGE; CLINICAL TRIAL; DRUG EFFECT; DRUG SAFETY; FIBRINOLYTIC THERAPY; HUMAN; LONG TERM CARE; MORTALITY; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; TREATMENT OUTCOME;

EID: 0035948696     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.286.4.442     Document Type: Article

References (71)

1. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction
2. Fibrin-selective thrombolytic therapy for acute myocardial infarction
3. The fibrinolytic system and thrombolytic therapy
4. The open-artery theory is alive and well - Again
5. Optimizing the medical management of acute coronary syndromes
6. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction
7. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction
8. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction
9. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion: Importance of early and complete infarct artery reperfusion
10. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction
11. A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction
12. Equivalence trials
13. Biochemical properties of the kringle 2 and protease domains are maintained in the refolded t-PA deletion variant BM 06.022
14. Protein engineering of novel plasminogen activators with increased thrombolytic potency in rabbits relative to activase
15. Pharmacokinetics and thrombolytic properties of deletion mutants of human tissue-type plasminogen activator in rabbits
16. Pharmacokinetic and distribution analysis of variant forms of tissue-type plasminogen activator with prolonged clearance in rat
17. Functional effects of asparagine-linked oligosaccharide on natural and variant human tissue-type plasminogen activator
18. A slow clearing, fibrin-specific, PAI-1 resistant variant of tPA (T103N, KHRR 296-299 AAAA)
19. A faster-acting and more potent form of tissue plasminogen activator
20. New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA
21. TNK-tissue plasminogen activator in acute myocardial infarction
22. Open, non-controlled dose-finding study with a novel recombinant plasminogen activator (BM 06.022) given as a double bolus in patients with acute myocardial infarction
23. Dose finding with a novel recombinant plasminogen activator (BM 06.022) in patients with acute myocardial infarction
24. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction
25. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction
26. Evaluation of a weight-adjusted single-bolus plasminogen activator in patients with myocardial infarction
27. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction
28. The Thrombolysis in Myocardial Infarction (TIMI) trial: Phase I findings
29. Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction
30. Lower dose heparin with thrombolysis is associated with lower rates of intracranial hemorrhage
31. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT)
32. A comparison of reteplase with alteplase for acute myocardial infarction
33. Intravenous nPA for the treatment of infarcting myocardium early
34. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction
35. Omission of heparin bolus lowers rate of intracranial hemorrhage with lanoteplase
36. Lower dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage
37. Pre-hospital initiated vs. hospital initiated thrombolytic therapy
38. Pre-hospital thrombolytic therapy in patients with suspected acute myocardial infarction
39. Halving of mortality at 1 year by domiciliary thrombolysis in the Grampian Region Early Anistreplase Trial (GREAT)
40. Thrombolysis medication errors: Benefits of bolus thrombolytic agents
41. Caution needed in interpreting the impact of dosing errors: A case study from ASSENT 2
42. Bolus fibrinolysis: Risk, benefit, and opportunities
43. Individual risk assessment for intracranial haemorrhage during thrombolytic therapy
44. Hirudin in acute myocardial infarction: Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial
45. Hirudin in acute myocardial infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B Trial
46. A randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes
47. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes
48. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction
49. Risk of intracranial haemorrhage with bolus versus infusion thrombolyric therapy: A meta-analysis
50. Safety outcomes in meta-analyses of phase 2 vs phase 3 randomized trials
51. Intracranial haemorrhage with bolus thrombolytic agents
52. An experimental model of intracranial hemorrhage during thrombolytic therapy with t-PA
53. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction
54. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction
55. Thrombolytic therapy with tissue-plasminogen activator or streptokinase induces transient thrombin activity
56. High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction
57. Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardia infarction
58. GPIIb/IIIa antagonists: Pathophysiologic and therapeutic insights from studies of c7E3 Fab
59. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with integrilin in acute myocardial infarction
60. Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban
61. Abciximab facilitates the rate and the extent of thrombolysis
62. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction
63. Combination reperfusion therapy with abciximab and reduced dose reteplase
64. Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction
65. Combination reperfusion therapy for acute myocardial infarction with eptifibatide and tenecteplase
66. The HART-II trial results: Late-breaking clinical trials
67. Dalteparin and tPA: The ASSENT-Plus Trial
68. Recombinant staphylokinase variants with altered immunoreactivity, I: Construction and characterization
69. Recombinant staphylokinase variants with altered immunoreactivity, II: Thrombolytic properties and antibody induction
70. Polyethylene glycol-derivatized cysteine-substitution variants of recombinant staphylokinase for single bolus treatment of acute myocardial infarction
71. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition